Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
3(60.0%)
N/A
2(40.0%)
5Total
Phase 2(3)
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05481697Not ApplicableRecruiting

Unintentional Weight Loss and Cancer: A Prospective Trial of Patient-centered Weight Tracking Combin

Role: collaborator

NCT02570542Phase 2Active Not Recruiting

Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Role: collaborator

NCT05176236Not ApplicableCompleted

Pictographic Education Handout on Tracheostomy Care

Role: collaborator

NCT00054249Phase 2Completed

T900607 in Treating Patients With Gastroesophageal Junction Cancer

Role: lead

NCT00054262Phase 2Completed

T900607 in Treating Patients With Unresectable Liver Cancer

Role: lead

All 5 trials loaded